MEDICLIN (MED) AI Stock Analysis

1 Followers

MEDICLIN

(XETRA:MED)

Select Model

Rating:64Neutral

Price Target:EUR 6.00▲(12.15% Upside)

Action:reiterated

Date:08/25/26

The score is driven primarily by improving financial performance (recovering profitability and solid, consistently positive free cash flow), balanced by still-elevated leverage that limits flexibility. Technically, the stock is in a strong uptrend but looks overbought (very high RSI/Stoch), which raises near-term pullback risk. Valuation is supportive due to the low P/E, while the modest dividend yield provides limited additional support.

Positive Factors

Revenue and Profitability RecoveryImproving revenue growth and a return to profitability indicate recovery in operating performance. Sustained demand across acute care, rehabilitation, and nursing services could support further earnings normalization over the next several quarters.

Negative Factors

Elevated LeverageDebt remains substantial relative to equity despite recent improvement. High leverage can constrain investment, increase sensitivity to financing costs, and reduce the company’s ability to absorb weaker occupancy, reimbursement pressure, or higher staffing expenses.

MEDICLIN (MED) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 254.12M
Dividend Yield: 0.75%
Average Volume (3M): 7,328
Price to Earnings (P/E): 8.7
Beta (1Y): 0.30
Revenue Growth: 2.94%
EPS Growth: -14.28%
Country: Germany
Employees: 7,677
Sector: General
Sector Strength: 55
Industry: Medical - Care Facilities

MEDICLIN Business Overview & Revenue Model

Company Description

Mediclin AG is a German healthcare enterprise primarily engaged in managing hospitals across the nation. Its operations are categorized into three main segments: Post-Acute, Acute, and various other related activities. The company offers a comprehens...

How the Company Makes Money

MEDICLIN makes money primarily by delivering healthcare services through its facilities and receiving reimbursement from payers. Key revenue streams typically include: (1) Acute care (hospitals/clinics): revenue generated from inpatient and outpatien...

MEDICLIN Financial Statement Overview

Summary

Operating performance is improving with steady revenue growth (~6.6% TTM) and profitability recovering from a 2023 loss (TTM net margin ~3.7%, EBIT margin ~5.4%). Cash flow is a strength with solid, consistently positive free cash flow (~€51.6M TTM). Offsetting this, leverage remains elevated (debt-to-equity ~1.5x TTM) and there is a noted data-consistency caution around the latest gross profit line.

Income Statement

64Positive

Balance Sheet

52Neutral

Cash Flow

71Positive

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Mar 2023	Dec 2021
Income Statement
Total Revenue	787.05M	784.49M	748.80M	730.10M	704.70M	673.10M
Gross Profit	-23.51M	113.81M	623.00M	594.60M	571.90M	551.00M
EBITDA	103.35M	98.66M	106.39M	101.26M	91.80M	85.43M
Net Income	29.11M	25.49M	24.84M	-10.78M	9.44M	1.46M
Balance Sheet
Total Assets	844.24M	879.69M	905.91M	880.50M	916.11M	881.24M
Cash, Cash Equivalents and Short-Term Investments	77.39M	72.18M	107.56M	115.29M	88.04M	133.48M
Total Debt	382.37M	390.83M	464.13M	479.82M	502.67M	439.96M
Total Liabilities	583.98M	630.06M	683.17M	684.47M	706.79M	698.22M
Stockholders Equity	259.56M	248.95M	222.51M	195.92M	209.21M	183.28M
Cash Flow
Free Cash Flow	51.58M	51.44M	35.88M	40.43M	8.62M	64.96M
Operating Cash Flow	92.50M	99.87M	80.57M	78.00M	34.64M	81.97M
Investing Cash Flow	-20.74M	-37.14M	-15.13M	-9.51M	-6.24M	-7.09M
Financing Cash Flow	-93.47M	-97.40M	-73.16M	-45.48M	-56.17M	-55.26M

MEDICLIN Technical Analysis

Technical Analysis SentimentPositive

Last Price5.35

Price Trends

50DMA5.35Negative

100DMA4.85Positive

200DMA4.26Positive

Market Momentum

MACD0.04Negative

RSI52.16Neutral

STOCH66.67Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:MED, the sentiment is Positive. The current price of 5.35 is above the 20-day moving average (MA) of 5.26, below the 50-day MA of 5.35, and above the 200-day MA of 4.26, indicating a neutral trend. The MACD of 0.04 indicates Negative momentum. The RSI at 52.16 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:MED.

MEDICLIN Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

DE:MED against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DE:M12	79Outperform	EUR 343.00M	17.49	16.58%	6.30%	-27.50%	13.64%
DE:LIK	67Neutral	EUR 154.50M	27.87	22.18%	1.94%	35.46%	17.88%
DE:MED	64Neutral	EUR 254.12M	8.73	11.54%	0.75%	2.94%	-14.28%
DE:RHK	61Neutral	EUR 957.22M	22.50	3.18%	1.39%	4.91%	11.71%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
DE:MAK	27Underperform	EUR 17.30M	-1.34	16.80%	―	2.73%	-1.80%

* General Sector Average

Performance Comparison

DE:MED and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:MED	MEDICLIN AG	5.35	1.91	55.39%
DE:RHK	RHON-KLINIKUM AG	14.40	2.59	21.95%
DE:MAK	MATERNUS-Kliniken AG	0.88	-0.21	-18.98%
DE:LIK	Limes Schlosskliniken AG	515.00	165.78	47.47%
DE:JTH0	Gesundheitswelt Chiemgau AG	11.60	-1.00	-7.94%
DE:M12	M1 Kliniken AG	19.06	5.22	37.76%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 25, 2026

MEDICLIN AI Stock Analysis